Literature DB >> 9690410

Co-administration of cyclosporin enables oral therapy with paclitaxel.

J M Meerum Terwogt, J H Beijnen, W W ten Bokkel Huinink, H Rosing, J H Schellens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9690410     DOI： 10.1016/s0140-6736(98)24030-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

Review 1.  Oral delivery of taxanes.

Authors:  M M Malingré; J H Beijnen; J H Schellens
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

3.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

4.  Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.

Authors:  Roos L Oostendorp; T Buckle; G Lambert; J S Garrigue; J H Beijnen; J H M Schellens; O van Tellingen
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

Review 5.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 6.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

7.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 8.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.

Authors:  Kai Jie Chen; Wan Yi Chen; Xia Chen; Yi Ming Jia; Gui Qin Peng; Li Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-17       Impact factor: 2.441

10.  Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats.

Authors:  K Kishore Kumar; Leena Priyanka; K Gnananath; P Ravindra Babu; S Sujatha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-05-29       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.